Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors

Annals of the Rheumatic Diseases

Volumn 72, Issue 12, 2013, Pages 2039-2046

  Maurer, Britta ^a   Distler, Alfiya ^b   Dees, Clara ^b   Khan, Korsa ^c   Denton, Christopher P ^c   Abraham, David ^c   Gay, Renate E ^a   Michel, Beat A ^a   Gay, Steffen ^a   Distler, Jörg H W ^b   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTIFIBROTIC AGENT; BLEOMYCIN; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSCRIPTION FACTOR FRA 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; TREATMENT RESPONSE; UPREGULATION;

FIBROBLASTS; SYSTEMIC SCLEROSIS; TREATMENT;

ADULT; ANIMALS; BENZAMIDES; BIOPSY; BLEOMYCIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROSIS; FOS-RELATED ANTIGEN-2; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 84887463104     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203729     Document Type: Article

References (17)

1. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
2. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
3. Daniels CE, Wilkes M, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16.
4. Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012;24:274-80.
5. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebocontrolled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011;63:3547-51.
6. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10.
7. Le Roy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
8. Eferl R, Hasselblatt P, Rath M, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 2008;105:10525-30.
9. Maurer B, Busch N, Jungel A, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009;120:2367-76.
10. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976;82:493-512.
11. Reich N, Maurer B, Akhmetshina A, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010;62:280-90.
12. Maurer B, Reich N, Juengel A, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012;71:1382-7.
13. Distler JH, Distler O. Criteria to select molecular targets for anti-fibrotic therapy. Rheumatology (Oxford) 2008;47(Suppl 5):v12-13.
14. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009;60:584-91.
15. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010;130:694-705.
16. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-8.
17. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study. Circulation 2013;127:1128-38.